Skip to main content

Table 3 Mean change in weekly dose/kg body weight between the baseline and evaluation periods in the PPS

From: A multicentre, multi-national, double-blind, randomised, active-controlled, parallel-group clinical study to assess the safety and efficacy of PDA10 (Epoetin-Alfa) vs. Eprex® in patients with anaemia of chronic renal failure

 

PDA-10 (n = 136)

Eprex® (n = 120)

Mean baseline epoetin dosage (IU/kg/week)

107.52 (69.18)

114.58 (73.86)

Mean evaluation epoetin dosage (IU/kg/week)

117.53 (81.35)

104.28 (65.87)

Mean absolute change in epoetin dose (IU/kg/week)

10.01 (44.64)

−10.30 (56.09)

Least Square mean difference of “PDA10 – Eprex®”

LS mean

9.55 (4.81)

−8.71 (4.82)

LS mean for difference

18.26 (6.02)

95% one-sided lower limit (≥ − 0.5) (p value)

8.31 (< 0.0001)

95% one-sided upper limit (≤ + 0.5) (p value)

28.21 (< 0.0001)

  1. IU international unit, LS least square